ADCs : antibodies and cytotoxic molecules united against tumours
Contexte historique des ADC L’histoire des immuno-conjugués appelés Antibody-Drug Conjugate ou ADC en anglais, ces biomédicaments révolutionnaires en oncologie, remonte aux travaux visionnaires de Paul Ehrlich, un scientifique allemand du début du 20ème siècle. Paul Ehrlich est souvent considéré comme le père de l’immunologie moderne et de la chimiothérapie. Son concept de « balle magique […]
breast cancer
The MabDesign market analysis for this month of pink October gives you an overview of market dynamics and projects in development targeting the treatment of breast cancer.
Multiple Sclerosis
This month’s MabDesign market analysis gives you an overview of market dynamics and development projects targeting the treatment of multiple sclerosis.
The immuno-oncology market
Long considered as cellular debris with no biological function, exosomes, and more generally extracellular vesicles (EVs), are now recognized as vectors of biological material with a role in intercellular communication. The building of knowledge on the subject has not only highlighted their role in certain pathologies, but also revealed their potential as biomarkers and therapeutic tools.
Glioblastoma
This month’s MabDesign market analysis gives you an overview of market dynamics and pipeline projects targeting the glioblastoma.
Therapeutic vaccines in oncology
This month, MabDesign’s market analysis provides an overview of the market for therapeutic oncology vaccines.
